In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding
In a statement, Novo Nordisk said the rapprochement between the two companies is "a meaningful win for patients in the US" and will expand access to Ozempic and Wegovy, adding that the two products have been "evaluated for safety and efficacy." The company also said that it "welcomes Hims & Hers shifting their GLP-1 business model to focus on increasing access to affordable, branded FDA-approved medicines." It has also agreed to drop its lawsuit with Hims & Hers that followed the compounded oral semaglutide announcement
Archived from the original on 2 February 2019
Klinic connects you with qualified medical professionals, giving you access to effective alternatives like Wegovy (semaglutide) and Zepbound (tirzepatide)
Whole-cell T4 is marketed as RGN-352 in the clinical development of RegeneRx for corneal diseases
The reports will reveal key insights on your energy, macronutrient, micronutrient, and fluid intake